We investigated early immunological reconstitution and the production of circulating inflammatory mediators and their relationship to aGVHD in children during the first 100 days following unrelated UCBT. Nine patients had an underlying malignant disease (ALL, ANLL), and two, non-malignant diseases (SAA, ALD). The median age was 10 years (range: 1.25-21). Seven of 11 patients were alive by day 100, two died from regimen-related toxicity, and two died from severe aGVHD (grade уIII). Myeloid engraftment (ANC у500/mm 
Umbilical cord blood is being increasingly used as an alternative source of allogeneic stem cells for the treatment of both malignant and non-malignant disorders. [1] [2] [3] [4] We and others 2, 4 have previously reported that myeloid recovery (у500/mm 3 ) occurs at a median of 23 days and platelet recovery (у50 000/mm 3 ) at a median of 75 days following unrelated cord blood transplant (UCBT). Several reports on the number of days to myeloid recovery following nonmobilized matched related and unrelated bone marrow transplantion 5, 6 appear to be similar to that following UCBT (median of 21.5 and 19 days, respectively). However, time to platelet recovery appears to occur earlier in matched related and unrelated BMT (median of 20.5 and 27 days, respectively) compared to UCBT.
The incidence of grade III and IV acute graft-versus-host disease (aGVHD) in children following unmanipulated (non T-depleted) unrelated BMT has been reported to be around 49%, 7 while the reported incidence of grades III and IV aGVHD following UCBT appears to be significantly lower (9-12%). 2, 4 Predictors for the development of aGVHD in children following allogeneic BMT are currently being investigated, but recent evidence suggests a possible correlation between elevated serum levels of soluble IL-2R␣ subunit on days 4 and 14 and the development of уgrade II aGVHD post related allogeneic BMT. 8 Additionally, there is still a high incidence of infectious morbidity during the first 100 days post UCBT.
2,4 Kurtz-
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berg et al 2 reported that out of 25 UCBT recipients, eight died within the first 100 days of transplantation from interstitial pneumonia (IP) (n = 3), aspergillus (n = 2), toxoplasmosis (n = 1), and CMV (n = 1). Although immune reconstitution occurs earlier following autologous compared to allogeneic BMT, 9 complete immune reconstitution eventually occurs within the first 2 years unless chronic GVHD develops. 10, 11 Few reports regarding the time of immunological reconstitution following unrelated UCBT are available. Early NK cell and B cell recovery, within the first 2-3 months, 12, 13 with inversion of the CD4:CD8 cell ratio due to earlier CD8 + cell recovery have been reported, 2, 13 however, T cell proliferative responses remain decreased within the first 100 days post UCBT. 2, 12, 13 In the present study we evaluated early immunological recovery (B cells, T cells, T cell functional studies, polymorphonuclear cell (PMN) functional studies, immunoglobulin levels), and correlated the circulating levels of inflammatory/cytokine mediators to the development of both low grade (0-I) and high grade (II-IV) aGVHD in UCBT recipients during the first 100 days post UCBT.
Materials and methods

Patients and eligibility
Patients were eligible for an unrelated UCBT if an HLAidentical sibling or a matched unrelated donor was not available in a reasonable period of time as determined by their specific clinical condition.
Between February 1995 and September 1996, a total of 11 patients underwent a UCBT. Three received grafts that were matched by serology at class one (HLA: A and B) and high resolution DNA typing at DRB1, and eight received grafts that were mismatched at one or two HLA loci (Table 1) .
Preparative regimens and GVHD prophylaxis
The first two ALL patients (141, 145) received fractionated total body irradiation (TBI) (1200 cGy), etoposide (50 mg/kg), cytosine arabinoside (600 mg/kg), and cyclophosphamide (90 mg/kg) for patient 141, and the same dose of TBI and cyclophosphamide but different doses of etoposide (1500 mg/m ) and cyclophosphamide (120 mg/kg). Patient 186 with severe aplastic anemia (SAA) received fractionated TBI (1200 cGy) and cyclophosphamide (120 mg/kg) ( Table 1) .
For GVHD prophylaxis, cyclosporin A (CsA) alone was used in patient 141, CsA and methotrexate (MTX) were used in patients 145 and 187, CsA and methylprednisolone were used in five patients (155, 158, 160, 185, 186), CsA and anti-thymocyte globulin (ATG) were used in two patients (195, 198) , and a combination of CSA, ATG and methylprednisone were used in patient 203 (Table 1) .
Supportive care
All patients were placed in single rooms ventilated with high efficiency particulate air filtration system. Trimethoprim-sulfamethoxazole (5 mg/kg/day utilized for PCP prophylaxis) was given daily until day −2 prior to transplantation and was resumed on a 3 day/week regimen after ANC у500/mm 3 for 3 days. For CMV prophylaxis, acyclovir (250 mg/m 2 every 12 h) alone was used in CMV serologically negative patients, and was started on day −5 until ANC recovered to у500/mm 3 . Acyclovir was followed by gancyclovir (5 mg/kg every 12 h for 5 days, then 5 mg/kg every day until day +100) after ANC у750/mm 3 for 2 days in CMV serologically positive patients or in recipients of serologically positive umbilical cord blood grafts.
Immunoglobulin therapy (IVIG) (200 mg/kg/dose) was started on day −1 and was given weekly until day +100, then monthly until 1 year post UCBT or until immune suppressive medications were discontinued, whichever occurred last. GM-CSF (250 g/m 2 /day) was started on day 0, and was changed to G-CSF (10 g/kg/day) when WBC count was у200/mm 3 for 2 days, and continued until ANC у2500/mm 3 for 2 days.
Engraftment
Myeloid engraftment was defined as an ANC у500/mm 3 the first day of 3 consecutive days. Platelet engraftment was defined as a platelet count of у20 000/mm 3 on the first day untransfused for 7 consecutive days. Restriction fragment length polymorphism (RFLP) was used to determine the degree of donor cell engraftment (chimerism) after myeloid recovery and on days 60, 100, 180 and 360 post transplant. 14 
Collection and processing of UCB
Cord blood units were collected, processed and kindly provided by Dr Pablo Rubinstein at the New York Blood Center, and were delivered frozen by overnight express. The cord blood units were placed in sterile bags and were thawed in a 38°C water bath. An equal volume of dextran/ albumin solution was added, the product was centrifuged and the supernatant removed. The cell pellet was resuspended in dextran/albumin according to Rubinstein et al 15 and was infused into the patient over 20-30 min.
HLA typing
HLA typing of donor cord blood and recipient blood was done by serology for both class one (HLA-A and B) and class two (DR) antigens, and by high resolution molecular DNA techniques for HLA-DRB1 typing. A match was 537 TBI = total body irradiation; VP16 = etoposide; ARA-C = cytosine arabinoside; CTX = cyclophosphamide; CsA = cyclosporin A; MTX = methotrexate; MPred = methylprednisolone; ALL = acute lymphoblastic leukemia; ANLL = acute non-lymphoblastic leukemia; MDS = myelodysplastic syndrome; ALD = adrenoleukodystrophy; SAA = severe aplastic anemia.
defined as a 4/6, 5/6 or 6/6 match by serological matching at A and B, and high resolution molecular typing at DRB1.
Colony assays
Colony-forming unit (CFU) assays were performed by suspending cells in methylcellulose medium (Methocult; Stem Cell Technologies, Vancouver, BC, Canada), erythropoietin (Amgen, Thousand Oaks, CA, USA), and PHA-LCM (Stem Cell Technologies). Mononuclear cells at a concentration of 10 5 /ml were plated in triplicate in 24-well tissue plates and were incubated at 37°C and 5% CO 2 . Colonies were scored after 14 days, and colonies with у50 cells were counted. Results were expressed as the median Ϯ s.e.m. 16 
Immunophenotype cell subset analysis
Aliquots of umbilical cord blood cells were obtained prior to transfusion, were suspended in FACS buffer solution (BDIS), and incubated with the recommended volume of fluorescent-conjugated monoclonal antibody markers for CD34 (HPCA2; Becton Dickinson (BDIS), Mountain View, CA, USA), and CD41 (Immunotech,Westbrook, ME, USA) in an ice water bath for 30 min. Lysing reagent was then added, followed by incubation on a bench rotator for 10 min. The cells were washed twice using FACS buffer solution (BDIS) and were fixed with 2% paraformaldehyde before FACS analysis was performed. 17 Analysis was done on a FACS Vantage dual laser flow cytometer (BDIS) with gating performed on linear forward scatter (FSC) and side scatter (SSC) and evaluation of populations on log fluorescence 1 (FL1), fluorescence 2 (FL2), and fluorescence 3 (FL3). The data were analyzed using Cell Quest software (BDIS). Immunophenotypic analysis of patient blood samples obtained on days 30 and 90 post UCBT was also done using the same technique. The cells were prepared with fluorescent-conjugated markers for CD3, CD3/4, CD3/8, CD2, CD5, CD19, CD56 and CD11b (BDIS, San Jose, CA, USA). 17 Analysis was done on a FACS Vantage dual laser cytometer (BDIS) with gating of the cell populations of interest using leukogate parameters.
T cell functional assay
Lymphocyte proliferative response to activation with mitogens (phytohemagglutinin (PHA) and pokeweed mitogen (PWM)) was determined on days 30 and 90 post transplantation. Patients' peripheral blood MNC were co-incubated with PHA or PWM in 96-well U bottom plates, at 37°C and 5% CO 2 , for 72 h. Cell cultures were pulsed with 3 H thymidine, 1 Ci/well, and after 6 h, were harvested and counted on a ␤ scintillation counter. Results were expressed as counts per minute (c.p.m.), and c.p.m. values for normal controls were у75 000 for PHA and у25 000 for PWM. 18 
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Neutrophil function
Recovery of neutrophil function was evaluated on days 30 and 90 post UCBT by testing for bacterial killing, 19, 20 chemotaxis, 21, 22 and superoxide production 21, 23 of neutrophils using previously described methods. Bacterial killing capability was measured by a modification of the Quie method. 20 Staphylococcus aureus was subcultured to obtain maximum phase growth, and then opsonized with control or cord blood serum for 10 min before the assay. Patient neutrophils were mixed with the opsonized bacteria at a ratio of 1:4 and incubated for 15 min at 37°C. Aliquots of bacteria/neutrophil mixtures were then plated (after serial dilutions in sterile water) in warm nutrient agar. The percent of bacterial killing was measured at 15 min and 30 min of bacterial culture with patient and normal control neutrophils, and the results were expressed as percent bacteria killed. 19 The Gallin modification of the Boyden chamber technique was performed for chemotaxis assay. 19, 22 Briefly, patient and control neutrophils were placed in a Boyden apparatus with two filters to separate the upper and lower chambers. Neutrophils were labeled with sodium 51-chromate, incubated at 37°C for 90 min in the upper chamber, and the lower chamber was filled with E. coli filtrate and 1.0% patient or control serum. After incubation, the filters were separated and counted in a scintillation counter. Similarly, aliquots of 100% chromium-labeled neutrophils were also analyzed and results expressed as mean % chemotaxis (migrated cells c.p.m./100% labeled cell c.p.m.).
Superoxide generation was quantified by measuring the stoichiometric reduction of cytochrome C by O 2 − . 21, 23 Both patient and control PMNs were compared following PMA stimulation and the incubation with cytochrome C for 10 min at 37°C. Similar tubes containing superoxide dismutase were used as blanks (to determine the non-O 2 − reduction of cytochrome C). After incubation, the cells were cooled on ice, centrifuged, and the supernatants' OD 550 measured by spectrophotometry. Results were expressed as mean nm of O 2 − /10 7 neutrophils. 3 untransfused × 7 days) following UCBT. The median number of days to myeloid recovery was 24, and the median number of days to platelet recovery was 52. Nine patients were evaluable for engraftment, 9.9 patients achieved myeloid recovery within 81 days, and only 5/9 patients had platelet engraftment within the first 100 days.
Serum immunoglobulin analysis
Serum levels of IgG, IgA and IgM were measured on days 30 and 90 using Rate Nephelometric assay (Beckman, Fullerton, CA, USA) as previously described. 24 The normal ranges for serum levels of IgG, IgA and IgM were previously determined by our clinical laboratory.
Inflammatory/Cytokine mediators
Serum for IL-2 receptor ␣ subunit (IL-2R␣), IL-2, IL-4, IL-7, IL-12 and IFN-␥ quantification was obtained 7 days before UCBT and on days 3, 7, 14, 30 and 60 post UCBT. Serum samples were stored at −80°C until analyzed. Serum IL-2R␣ concentrations were measured by a sandwich enzyme-linked immunosorbent assay (ELISA) (Biosource, Camarillo, CA, USA) consisting of a mouse monoclonal IL-2R antibody (capture antibody) and a goat polyclonal IL-2R antibody (detection antibody). Serum IL-2 concentrations were measured by a sandwich ELISA (Biosource) consisting of a mouse anti-human IL-2 monoclonal antibody (capture antibody) and a goat anti-human IL-2 polyclonal antibody (detector antibody). Serum IL-4 concentrations were measured by a sandwich ELISA (Biosource) consisting of a mouse monoclonal IL-4 antibody (capture antibody) and a mouse monoclonal IL-4 antibody (detection antibody). Serum IL-7 concentrations were measured by a sandwich ELISA (Biosource) consisting of a rat monoclonal IL-7 antibody (capture antibody) and a rat monoclonal IL-7 antibody (detection antibody). Serum IFN-␥ concentrations were measured by a sandwich ELISA (Biosource) consisting of a mouse monoclonal IFN-␥ antibody (capture antibody) and a rabbit polyclonal IFN-␥ antibody (detection antibody). The Biosource kit's IFN-␥ was used as the standard and positive control. Serum IL-12 concentrations were measured by a sandwich ELISA (R&D Systems, Minneapolis, MN, USA) consisting of a mouse monoclonal IL-12 antibody (capture antibody) and a goat polyclonal IL-12 antibody (detection antibody). The sensitivities of these assays are: IL-2R␣ Ͻ16 pg/ml; IL-2 Ͻ8.7 pg/ml; IL-4 Ͻ2 pg/ml; IL-7 Ͻ9 pg/ml; IFN-␥ Ͻ4 pg/ml; IL-12 Ͻ0.5 pg/ml. All samples were run in triplicate, and data expressed as the mean Ϯ standard error of the mean (s.e.m.).
Statistical analysis
Statistical analysis was performed using one-way analysis of variance followed by Dunnett Multiple Comparisons or the Kruskal-Wallis nonparametric analysis of variance (In Stat statistical program, Graph Pad Software, San Diego, CA, USA). P values Ͻ0.05 were considered significant.
Results
Patient characteristics and outcome
The median age of our patient population was 10 years (range: 1.25-21), and the median weight was 28.4 kg (range: 10.9-65). The underlying diseases included the following: ALL in second remission in three patients, ALL in third remission in one patient, ANLL in first remission in four patients, ANLL in second remission in one patient, severe aplastic anemia (SAA) in one patient and adrenoleukodystrophy (ALD) in one patient (Table 1) .
Two patients died (158, 187) prior to day 30 post UCBT secondary to regimen-related toxicity and never achieved myeloid or platelet recovery. Two patients died of severe aGVHD (grade уIII) after day 30 and before day 100 post UCBT (185,198). Aspergillus sinusitis was diagnosed in one patient who died on day +26 post UCBT and Streptococcus mitis septicemia and meningitis were diagnosed in another patient who died on day +84 post UCBT.
Characteristics of UCB units
The median volume of UCB units infused was 75.1 ml (range: 48.8-131.6 ml). The median nucleated cell (NC) dose per kg was 2.3 × /kg (range: 0.8Ϫ10.6) ( Table 2) . 
Hematopoietic recovery and engraftment
Myeloid engraftment was evaluable in nine out of 11 patients and occurred at a median of 24 days (range: 14-55). Platelet engraftment occurred in five patients at a median of 52 days (range: 33-95) (Figure 1a and b) .
Acute graft-versus-host disease (aGVHD) and inflammatory mediators
The two patients who died in the first 30 days of transplantation before achieving myeloid engraftment were unevaluable for aGVHD analysis. Grade II-IV aGVHD developed in seven out of nine evaluable patients (78%), and grade 0-I aGVHD developed in two patients (22%). However, severe aGVHD grade III-IV occurred in five patients (55%) and resulted in two deaths (22%) by day 100 post UCBT. A total of four patients (44%) died of aGVHD grade IV by day 150 post transplantation. The percent of fatal aGVHD varied with HLA parity and was 100% for 4/6, 50% for 5/6 and 0% for 6/6 matched unrelated UCBT (Table 3) . Serum sIL-2R␣ sub-unit level (mean Ϯ s.e.m.) on day 7 post UCBT was 2225 Ϯ 975 pg/ml for patients with less severe grade 0-I aGVHD, and was 2033 Ϯ 352 pg/ml for patients with grade II-IV aGVHD (P = 0.8). The serum level of sIL-2R␣ sub-unit continued to be similar between patients with grade 0-I and grade II-IV aGVHD throughout the first 30 days post UCBT (Figure 2a) . Serum levels of other inflammatory cytokines were also measured. Serum levels of IL-2, IL-4, IL-7, IL12 and IFN␥ (mean Ϯ s.e.m.) on day 7 post UCBT were not significantly different between patients with grade 0-I aGVHD and patients with grade II-IV aGVHD (Figure 2a, b, and c) .
Immunological reconstitution
The number of B cells (CD19 + ) increased between day 30 and day 90 from a mean of 4.0 Ϯ 1. 
Discussion
Following UCBT, this group of 11 children achieved myeloid recovery after a median of 24 days, which was comparable to the experience of other investigators with UCBT (median 22-25 days), [2] [3] [4] [25] [26] [27] unmobilized autologous (median 23 days), 28 unmobilized allogeneic-related (median 21.5 days), 6 and unrelated BMT (median 19 days), 5 but longer following mobilized autologous peripheral blood stem cell transplantation (PBSCT) (median 11 days). 29 However, platelet engraftment was delayed and occurred at a median of 52 days, as similarly reported by other investigators following UCBT (median 54 days), 4 but longer than the reported platelet recovery time following unmobilized autologous BMT (median 33 days), 28 unmobilized-related BMT (median 20 days), 6 unrelated BMT (median 27 days), 5 and mobilized PBSCT (median 10 days). 29 The median nucleated cell dose of 2.3 × 10 7 /kg for our group of UCBT patients was one log lower than the median dose reported for rapid engraftment following unmobilized allogenic BMT, unmobilized autologous BMT, and mobilized autologous PBSCT. 5, 30, 31 The median CFU-GM dose of 1.1 × 10 4 /kg was within the reported range for rapid engraftment following unmobilized allogenic BMT 32 and unmobilized autologous BMT, 30 but was lower than the reported CFU-GM dose infused following mobilized autologous PBSCT. 33 The median numbers of infused CD34 /kg, respectively, and were one log lower than the threshold dose previously reported for rapid platelet engraftment following mobilized autologous PBSCT 34 and may account in large part for the delay in platelet recovery observed in this study.
Early markers of severe aGVHD could not be identified in our group of UCBT patients. Serum levels of soluble IL-2R (sIL-2R), although increased post UCBT within the first week, were not higher in patients with more severe aGVHD grade II-IV as compared to patients with grade 0-I aGVHD, and could not predict early onset of severe aGVHD. This finding was in contrast to what was reported by other investigators, 8, [35] [36] [37] who found a significant elevation of sIL-2R as early as 3 days 8 or up to 2 weeks 36 post allogeneic BMT in patients with aGVHD that correlated with the severity of aGVHD and returned to normal levels when aGVHD was clinically controlled.
Immunological reconstitution following different types of stem cell transplantation has been extensively studied, but few data are available following UCBT. 25 Umbilical cord blood T cells have been shown in vitro to be functionally immature, incapable of generating significant levels of cytotoxic T lymphocytes (CTLs) in mixed lymphocyte cultures, and 10-1000 times less alloreactive than adult T cells in proliferative and cytotoxic T cell studies. Umbilical cord blood was equivalent to adult blood in NK and lymphokine activated killer (LAK) cell precursors. Umbilical cord blood was also found to produce little IL-4, IL-6, TNF-␣, and INF␥ upon alloantigen stimulation. 38 This group of 11 patients undergoing UCBT has demonstrated early NK cell recovery (day 30) similar to earlier reports following UCBT and allogeneic BMT.
11,39 B cell recovery occurred early (day 90) as previously reported post UCBT 2,12,13 in contrast to allogeneic BMT. 10, 11, 39 Neutrophil functions (bacterial killing, superoxide production and chemotaxis) also recovered within the first 100 days post UCBT in these patients. However, similar to earlier reports post allogeneic BMT, 10, 11 T cell and T cell subsets remained low. In contrast to previous reports following UCBT 2, 13 and allogeneic BMT, 10,11,39 we did not observe an inversion of the CD4:CD8 ratio (2.5 on day 30, 3.2 on day 60 and 1.2 on day 90) within the first 100 days post transplantation. Our group of patients has shown decreased mitogen proliferative responses to PHA, PWM and Con A, similar to earlier reports post UCBT and allogeneic BMT. 2, 12, 13, 39 Immunoglobulin levels remained normal throughout the study period. IgG levels may have been influenced by IVIG therapy, but IgA and IgM recovery were earlier than previously reported following UCBT 13 and T cell-depleted allogeneic BMT in children. 10 In conclusion, unrelated UCBT can result in similar myeloid recovery as seen in non-mobilized allogeneic BMT recipients, but associated delayed platelet reconstitution may require further investigation and intervention to potentially decrease the morbidity resulting from prolonged thrombocytopenia. Early predictors of severe aGVHD development require identification, in order to assist in early and adequate therapy of patients at increased risk. Lastly, immunological reconstitution, particularly T cell subsets and functions, appears to be delayed in this small group of patients and may account for the infectious and immunological morbidity seen in this early critical period post UCBT. New methods to ex vivo and/or in vivo expand and/or functionally activate mature T cell immune effector subsets need to be identified in order to reduce infectious morbidity and/or mortality and enhance cancer immune cellular immunoreactivity without exacerbating aGVHD following unrelated UCBT.
